The disease is one that progresses slowly, and the pharmaceuticals that are currently available are only able to alleviate the symptoms," says Kaj Blennow, professor at the Sahlgrenska Academy, and a world-leading researcher in the field.
Several biomarkers have been identified in recent years.
Biomarkers are proteins that can be detected in the cerebrospinal fluid and used to diagnose Alzheimer's disease.
It is now clear that the typical pattern of biomarkers known as the "CSF AD profile" can be seen in the cerebrospinal fluid of patients even with very mild memory deficiencies, before these can be detected by other tests.
"The patients who had the typical changes in biomarker profile of the cerebrospinal fluid had a risk of deterioration that was 27 times higher than the control group.
We could also see that all patients with mild cognitive impairment who deteriorated and developed Alzheimer's disease had these changes in the biomarker profile of their cerebrospinal fluid," says Kaj Blennow